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CASE PRESENTATION
A 61-year-old male dialysis patient was referred from another center to
the Bone and Mineral Research Unit of the Hospital Central de Asturias
for evaluation. At age 24, renal tuberculosis had necessitated a left
nephrectomy; at age 42 nephrolithiasis in the right kidney had prompted
surgical intervention. Four years later, moderate renal failure presumably
due to chronic interstitial nephritis was diagnosed; 7 years later, at age 53,
he entered the dialysis program. He received treatment in a dialysis unit
equipped with a reverse osmosis (RO) system for water treatment. Renal
osteodystrophy had been present since the beginning of dialysis, and the
thoracic and lumbar spine showed demineralization.
During the first 5 years of hemodialysis, symptoms and radiologic signs
of hyperparathyroidism, including multiple vascular calcifications, wors-
ened. The serum calcium (Ca1) level progressively increased, reaching
10.5 mg/dl. The serum phosphorus (P) level was high, although the patient
had received long-term treatment with aluminum hydroxide. During that
period, parathyroid hormone (PTH) levels (carboxy terminal) had re-
mained 40 to 50 times higher than the upper limit of normal. Total
alkaline phosphatase measurements had stayed in the low-normal range.
The patient needed frequent red cell transfusions to avoid symptoms of
anemia. Five years after beginning dialysis, he had a non-traumatic radial
fracture coincident with worsening of the radiologic signs and his symp-
toms. A subtotal parathyroidectomy was performed.
During the 2 years after the subtotal parathyroidectomy, his symptoms
mildly improved, and the carboxy terminal PTH level decreased, stabiliz-
ing in the upper limit of normal. Total alkaline phosphatase fell to lower
than normal, and the serum P was kept at acceptable values by aluminum
hydroxide and calcium carbonate. Oral calcitriol (1.5–3.5 mg/week) main-
tained serum Ca1 levels in the range of 10.0 mg/dl–10.5 mg/dl. Two years
after the parathyroidectomy, bilateral carpal tunnel syndrome was de-
tected and surgically relieved. Amyloid was detected in the surrounding fat
tissue, serum beta-2 microglobulin was elevated; dialysis with highly
permeable membranes (PAN) was prescribed.
Three years after the parathyroidectomy, PTH levels, measured several
times using a PTH intact assay, revealed very low values (from undetect-
able to 13.5 pg/ml) and total alkaline phosphatase had returned to
pre-surgery values (in the low-normal range). Basal serum aluminum (Al)
was 96 mg/liter, increasing to 234 mg/liter after the infusion of 40 mg/kg of
deferoxamine. Because Al-induced bone disease was suspected, a bone
biopsy with tetracycline labeling was performed. The main histologic and
histomorphometric findings of the bone biopsy were reduction in trabec-
ular bone volume (11%), a slight increase in relative osteoid surface
(20%), a decrease in osteoid volume (1.3%), low osteoblast surface
(0.12%), low osteoclast surface (0.59%), positive Al surface staining
(aluminum 16%; solochrome of azurine, 47%), and negative iron (Fe)
staining (Perls). Bone Al and Fe concentration, measured by atomic
absorption spectrometry, were 28 mg/g and 405 mg/g, respectively (normal,
3 mg/g and 300 mg/g, respectively). The tetracycline study showed only a
single and diffuse labeling. Aluminum-induced adynamic bone disease was
diagnosed.
After the bone biopsy, therapy with deferoxamine (40 mg/kg/week) was
prescribed (18 months of intermittent treatment over 3 years). During
deferoxamine therapy, repeated basal serum Al levels were 50–85 mg/
liter; these values doubled after the deferoxamine tests performed during
that period. At the end of deferoxamine treatment, the serum Al remained
at the same level, but intact PTH and alkaline phosphatase levels
progressively increased, reaching 150 pg/ml and 219 U/liter, respectively
(normal, 10–65 pg/ml and 70–280 U/liter). Before and after the deferox-
amine treatment, serum transferrin, serum Fe, and Fe-transferrin satura-
tion were always in the normal range. Two years after the bone biopsy,
when the patient was 62 years old, he suffered a fracture of the right
femoral neck; one year later, he fractured the left femoral neck. Both were
treated with standard surgical techniques.
During the following 4 years, the patient was admitted to the hospital
several times with diagnoses of diabetes mellitus type II, diverticulitis,
ventricular tachycardia, and congestive cardiac failure. Also, severe vas-
cular obstruction of the left leg necessitated amputation of the second toe
of the left foot. During the last year (7 years after the bone biopsy), he has
maintained a serum calcium ranging between 9.0–9.5 mg/dl; serum
phosphorus, 4.7–6.5 mg/dl; serum aluminum, 73.0–90.8 mg/liter; normal
serum iron parameters; intact PTH levels of 314–415 pg/ml; and an
alkaline phosphatase of 125–139 U/liter.
DISCUSSION
DR. JORGE B. CANNATA-ANDı´A (Head, Bone and Mineral
Research Unit, Professor of Nephrology, Instituto Reina Sofı´a
de Investigacio´n, Hospital Central de Asturias, Universidad de
Oviedo, Oviedo, Spain): This man had long-standing, slowly
progressive renal failure. When he entered the dialysis
program, his renal osteodystrophy was symptomatic. Most
of his signs and symptoms were interpreted as due to
secondary hyperparathyroidism (osteitis fibrosa), even
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though the total alkaline phosphatase levels were not in the
range of the severe forms of high bone remodeling. The
possibility of his having aluminum overload was not inves-
tigated. The first non-traumatic bone fracture, in associa-
tion with the worsening of his clinical symptoms, was
attributed to secondary hyperparathyroidism and prompted
subtotal parathyroidectomy; other diagnostic possibilities
were not considered.
Although osteitis fibrosa due to hyperparathyroidism is
the most frequent form of renal osteodystrophy in patients
entering a dialysis program, different factors can influence
bone remodeling and facilitate the appearance of low-
bone-remodeling lesions in patients with the slowly pro-
gressive forms of renal disease. A large proportion of
patients thus do not have a high-bone-remodeling lesion.
While symptoms and signs of renal osteodystrophy some-
times can indicate the diagnosis, just as often they provide
little help in distinguishing the type of bone lesion. In
addition, physicians at dialysis centers with adequate water
treatment systems (for example, RO) frequently underes-
timate the possibility of aluminum exposure contributing to
renal osteodystrophy.
In this patient, parathyroidectomy apparently improved
his signs and symptoms somewhat, but it is highly likely that
this operation adversely affected his subsequent course,
including the histologic bone pattern found 3 years later,
the bone fractures, and the persistent relative hypoparathy-
roidism. After long-term treatment with deferoxamine,
biochemical markers indicated slow but progressive im-
provement in bone remodeling. However, not until 10 years
after parathyroidectomy did his bone remodeling return to
acceptable levels.
The type of bone lesion and the concentrations of
aluminum and iron in this patient merit special comment.
While this patient received multiple red cell transfusions,
he apparently did not have a heavy aluminum load in his
dialysate. Moderate aluminum load from intermittent alu-
minum hydroxide treatment was present in this patient with
relative hypoparathyroidism, and he developed adynamic
bone disease instead of osteitis fibrosa. In this Forum, I will
review the importance of the association of iron load,
aluminum load, and relative hypoparathyroidism in pro-
ducing the various bone remodeling lesions.
Bone remodeling and renal osteodystrophy
Bone disease in patients with renal failure is not a
uniform metabolic disorder [1, 2]. As renal failure
progresses, the disordered patterns of bone metabolism
differ greatly among patients [2–5]. Decreased serum cal-
cium and 1,25 vitamin D synthesis plus retention of phos-
phate trigger secondary hyperparathyroidism, but several
factors modulate the severity and final outcome of this
disorder. Two main factors can modify the pattern and
form of presentation of renal osteodystrophy. (1) The first
group of factors is related to the underlying renal disease,
for example, diabetes or rapidly progressive glomerulone-
phritis. In these cases, the disease itself and/or the treat-
ment prescribed (for example, corticosteroids) as well as
the age of the patient result in particular forms of bone
lesions. When the patient presents with severe renal failure,
there is little we can do to modify or influence these
underlying factors. (2) The other set of factors is related to
the medical management of secondary hyperparathyroid-
ism and to the dialysis treatment itself. In these two
circumstances, the type and modality of treatment (hemo-
dialysis or CAPD), and also the use of different therapeutic
approaches (phosphate binders, vitamin D metabolites,
etc.) can introduce changes that affect the presentation and
evolution of the metabolic bone disorders of chronic renal
failure. As a result of the interactions of these several
factors, renal osteodystrophy can present with a wide
spectrum of bone derangements, ranging from high bone
remodeling—the classic pattern of disordered bone metab-
olism in chronic renal failure—to low bone remodeling. I
will focus my attention here on the latter, because recent
reports indicate a likely increase in its incidence and
prevalence in patients with chronic renal failure [3–9].
The literature contains several histologic classifications
of renal osteodystrophy [3, 5, 9]. It is beyond the scope of
this review to compare and analyze them. However, I
believe it useful to categorize the bone changes found in
uremia into high- or low-bone remodeling lesions. This
conceptual division offers an understandable framework of
the different forms of renal osteodystrophy, making easier
the application of different therapeutic strategies.
The concept of high- and low-bone-remodeling lesions
involves two main aspects: a difference in the number of
active bone remodeling units, and a difference in the level
of activity of each bone remodeling unit. The end product
of these two factors results in great differences in bone
formation rate, accounting for the wide spectrum of renal
osteodystrophy.
Low-bone-remodeling hypokinetic osteodystrophy, by
definition characterized by a low formation rate of bone,
essentially reflects the body’s lack of ability to form normal
bone matrix, mainly because of low cellular activity, and
also the body’s inability to mineralize bone adequately. The
two main histologic forms of low-bone-remodeling disease
are osteomalacia and adynamic bone disease. Both entities
present clear and objective pathophysiologic and histologic
differences. In osteomalacia, both osteoid deposition (os-
teoblast activity) and the rate of mineralization are re-
duced, but the reduction in mineralization is by far greater
than the reduction in osteoid formation [1, 5, 10]. The
reduced mineralization leads to an increase in non-miner-
alized osteoid (osteoid accumulation) and consequently to
an increase in osteoid volume. By contrast, adynamic bone
is characterized by low osteoid formation (osteoblast activ-
ity) and by a proportional reduction in bone mineralization,
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there being no specific impairment in the mineralization
process [1, 5, 7, 11].
Has the prevalence of the different forms of renal
osteodystrophy changed? Throughout the last 20 years, our
knowledge of renal osteodystrophy has expanded greatly.
Before, the pathogenetic mechanisms were poorly under-
stood, and we had less-accurate diagnostic methods and
fewer therapeutic possibilities [12, 13]. Over the last de-
cade, new therapeutic approaches have been introduced [1,
2, 4, 14]. As a result, we might expect to find differences in
the prevalence of the different types of renal osteodystro-
phy from that found in earlier studies [3–5, 6–9, 12, 13].
Unfortunately, the early studies of renal osteodystrophy
did not evaluate non-selected patients. Nevertheless, we
know that high bone remodeling (from mild to severe) was
the most common diagnosis, two to three times more
frequent than low bone remodeling [7, 13]. Thus, several
years ago, the predominant bone lesion in patients in whom
bone biopsy was performed was probably due to hyperpara-
thyroidism. The second most common diagnosis was alu-
minum-induced osteomalacia [5, 7, 8, 15]. The incidence of
this diagnosis varied greatly among centers, regions, and
countries [10].
By contrast, recent reports in non-selected patients [3, 4,
6, 8] as well as in patients in whom bone biopsy was
performed for specific medical reasons [5, 7] reveal that
low-bone-remodeling lesions are quite frequent, account-
ing in some series for almost one-half the lesions observed
[3, 4, 8]. This increase in the incidence of low-bone-
remodeling lesions seems to be due to the increase in
adynamic bone disease. On the other hand, the frequency
of the previously most common form of low bone turnover,
aluminum-induced osteomalacia, seems to have diminished
[4, 5]. Still, this assertion has a major limitation: the criteria
used to define adynamic bone have not been uniform. To
distinguish osteomalacia from adynamic bone disease, one
must have consistent cut-off levels to define normal, low,
and high osteoid volume. Although the upper limit of
osteoid volume in a normal population is considered to be
approximately 5% of bone volume, the most quoted studies
have used different limits to define low or high osteoid
volume. These limits have ranged between 5% in the first
studies [10] to 15% in the most recent publications [3, 4,
6–8]. Using the lower threshold (5%), more patients are
diagnosed with osteomalacia, but if higher limits are used
(12% to 15%), more patients are diagnosed as having an
adynamic bone disease, without real changes in the inci-
dence or the prevalence of these entities. The most recent
papers, which use limits for osteoid volume of 12% to 15%,
classify only the most severe cases of osteoid accumulation
as osteomalacia. This fact might well contribute to the
increased prevalence of adynamic bone disease compared
with osteomalacia [3, 4, 6, 8, 10], but it cannot account
entirely for the change observed in the frequency of the two
diseases. Although the criteria haven’t changed for either
osteomalacia or adynamic bone disease since 1983 [5, 7],
some authors have reported a decrease in osteomalacia and
an increase in adynamic bone disease. However, these
changes have occurred without an overall increase in the
aggregate number of the two low-bone-remodeling lesions;
the cumulative incidence has remained stable at approxi-
mately 25% of all bone biopsies throughout the last 12
years [5].
Aluminum toxicity, the main cause of low-bone-turnover
osteomalacia in the 1970s and 1980s, is now better man-
aged in most developed countries [16]. In other areas of the
world [17–19], however, aluminum toxicity remains a major
challenge. The change in the pattern of aluminum exposure
alone cannot explain the increase in the prevalence of
adynamic bone disease. Other factors likely have contrib-
uted to its increase. The type of patients undergoing
dialysis clearly has changed. Diabetics and older patients
now comprise a major segment of the dialysis population
[20, 21]. Diabetes as well as age have been indicted as
independent factors that can induce a decrease in bone
remodeling [4, 8, 22, 23]. The management of renal patients
also has changed. New therapeutic approaches keep sec-
ondary hyperparathyroidism under control, such as the
increasing use of calcium carbonate, calcium acetate, and
vitamin D metabolites [24, 25]. Bicarbonate has almost
replaced acetate as a buffer in hemodialysis [26]. All these
factors might have contributed to a greater suppression of
PTH function and to better control of metabolic acidosis,
with a consequent decrease in bone resorption [27, 28].
Similarily, in peritoneal dialysis patients, the stability in the
serum calcium and acid-base balance also has been impli-
cated in explaining the higher incidence of low bone
remodeling in these patients [9].
In chronic renal failure, our goal should be to achieve the
more adequate (“normal”) bone turnover. Therefore, be-
fore going further, it is important that we define the limits
between high, “normal,” and low bone turnover. Clinicians
generally agree that uremia results in a multifactorial
resistance to the action of PTH in bone; this concept is
known as “skeletal resistance to PTH.” In practical terms,
uremia necessitates a higher level of circulating PTH to
obtain adequate (“normal”) bone turnover. Although this
concept is rather old [18–20], accurate PTH assays, and
thus reliable serum values of PTH that precisely define the
concept of “skeletal resistance to PTH,” were not available
until recently [3, 4, 6].
To maintain a normal osteoblast surface, dialysis patients
require PTH levels in the range of 70–260 pg/ml; to obtain
a normal bone formation rate, they require PTH levels
between 100–170 pg/ml (reference values in subjects with
normal renal function, 10–65 pg/ml) [4]. Recent studies
suggest that because dialysis treatment only partially cor-
rects this skeletal resistance to PTH, predialysis patients
require higher parathyroid hormone levels (up to 375
pg/ml) to maintain a normal osteoblast surface and bone
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formation rate [4]. Therefore, the optimal PTH range that
we consider “normal” in chronic renal failure is 125–250
pg/ml in dialysis patients, and 300–375 pg/ml in predialysis
patients with advanced renal failure [4]. Values below 120
pg/ml provide a positive predictive value of 83% and 90%
for the diagnosis of low bone remodeling, in predialysis and
dialysis patients, respectively [4].
These figures are valid only for patients not receiving
vitamin D pulse therapy with calcitriol, which can directly
suppress bone formation. Therefore, particularly in severe
forms (diffuse or nodular hyperparathyroidism), calcitriol
pulse therapy does not always suppress PTH synthesis, but
it can reduce bone formation. Under these circumstances,
PTH levels will not reflect what is happening in bone [29,
30].
Parathyroid function in low bone remodeling. The forms of
renal osteodystrophy involving low bone remodeling are
associated with “relative” basal PTH deficiency [31, 32]. In
basal conditions, the circulating absolute levels of PTH are
normal or insufficiently increased to maintain adequate
bone turnover. The value of measuring basal PTH levels in
dialysis patients is limited because serum calcium, a major
regulator of PTH production and release, can induce a
wide range of intra- and extradialytic changes [33], making
comparison of PTH function among these patients difficult.
In addition, analysis of a single determination of calcium
and PTH provides information limited to only one point in
time.
More recently, new dynamic tests that assess parathyroid
function have helped us better understand the function of
the parathyroid gland in the different forms of renal
osteodystrophy [31, 34]. Analysis of the sigmoidal curve,
which relates serum calcium and PTH changes, tells us
about the sensitivity of the gland (slope of the curve and set
point), and dynamic tests help us judge the secretory
reserve capacity of the parathyroid cells [31, 34–36]. Un-
fortunately, the studies reported have not used similar
methods and therefore cannot be directly compared. Im-
portant factors such as phosphorus, pH (use of acetate or
bicarbonate), glucose, and magnesium have not been taken
into account. Another important factor, age of the patient,
has been consistently ignored; comparisons of studies con-
ducted in young people [53] with studies carried out in
older people [31–35], in whom the parathyroid gland is less
active, have limited value. Despite all these limitations, we
have gathered enough information to allow us to analyze
the responsiveness of the parathyroid gland in low bone
remodeling.
The first clinical studies of parathyroid gland responsive-
ness in low bone turnover were carried out in the early
1980s and compared patients with aluminum-induced os-
teomalacia with patients with high bone turnover (osteitis
fibrosa) [37, 38]. In both studies, patients with osteitis
fibrosa had, in absolute terms, a significantly greater re-
sponse to hypocalcemia than did the patients with osteo-
malacia. However, if we analyze the changes in PTH
response as a percentage of the basal values, we find that
both groups behaved in a similar way, with no differences in
the percentage increments. In other words, the larger the
gland, the greater the magnitude of the response [36–38].
Further studies inducing hypo- and hypercalcemia during
hemodialysis showed similar results. Lower absolute incre-
ments from hypocalcemia were found in patients with low
bone remodeling (with and without aluminum) than in
patients with high bone remodeling [31]. Adjustment of the
curves to show the maximal PTH (100%) of each group
demonstrated that the set point and the slope of the curve,
independent of the presence of aluminum, were lower in
patients with low bone remodeling. In another study, the
same group found that one year of treatment with defer-
oxamine did not increase the maximal absolute values of
PTH, but did shift the calcium-PTH curve to the right, and
the curve also had a slightly steeper slope [39]. This result
suggested that the removal of aluminum partially restores
the gland’s sensitivity. This finding is also supported by
another clinical study carried out after 6 months of contin-
uous deferoxamine administration [19].
More recently, another study investigated the maximal
and minimal PTH response in normal volunteers, in pa-
tients with adynamic bone disease, and in osteitis fibrosa in
CAPD patients [35]. As in previous studies, hypocalcemia
was followed by a lower absolute response in PTH levels in
CAPD patients with adynamic bone. When the results were
expressed as a percentage increase over basal PTH values,
however, the increments of PTH in adynamic patients were
in the same range as those in normal volunteers and were
even higher than those in patients with osteitis fibrosa. The
maximal PTH was reached slowly in the adynamic group
compared with the other two groups, but PTH levels
remained high for a longer period in patients with ady-
namic bone. This persistence demonstrated an adequate
secretory reserve in this group. On the other hand, after
calcium infusion, patients with adynamic bone demon-
strated, as in other studies [40], a lack of capacity to handle
calcium loads, and they had a more sustained hypercalce-
mia after the calcium infusion [35].
Another parameter used to investigate changes in the
sensitivity of the parathyroid gland has been the set point,
defined in clinical studies by the serum calcium concentra-
tion at which the maximal PTH is suppressed by 50%.
Although some studies have found a lower set point in low
bone remodeling, other studies have found no differences
in the set point in high, normal, or low bone remodeling
[35]. Thus, the value of the set point in these (and other)
circumstances remains controversial [39, 40]. I personally
believe that analysis of the slope of the calcium PTH curve
and its shift to the right or left gives better information
about the sensitivity of the parathyroid gland. The useful-
ness of the set point is more controversial; its value, which
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after all is a single measurement of the sensitivity of the
gland, likely has been overestimated.
In summary, the magnitude of change in PTH per unit of
change of serum calcium is lower in low bone remodeling.
This alteration indicates a reduction in the sensitivity of
parathyroid cells, independent of the presence of alumi-
num. Nevertheless, the maximal and minimal capacities of
the gland remain in a normal range. Overall, the informa-
tion available indicates that in low bone remodeling, the
parathyroid gland probably is slower to respond but its
secretory reserve is preserved.
Pathogenesis of low bone remodeling
I already have set forth the most frequent causes of low
bone remodeling in uremia. Now we will analyze in detail
the factors and likely mechanisms involved in the patho-
genesis of low bone remodeling. Among all causes of low
bone remodeling, the first cause described and the most
studied is aluminum-induced bone disease. In addition,
aluminum-induced bone disease is the only form of low-
bone-turnover producing symptoms and ultimately death
[3, 5, 8, 10, 15, 18, 41].
For this reason, some investigators classify low-bone-
turnover disease into two main types: aluminum-induced
and non-aluminum-induced low bone remodeling. This
classification allows us to recognize when aluminum is the
likely cause of the disease, when aluminum is not impli-
cated, and when aluminum is merely an “innocent bystand-
er.” This important topic has practical consequences, but
unfortunately we do not have definitive answers.
Aluminum-induced low bone remodeling. Aluminum tox-
icity produces two alterations in bone: osteomalacia and
adynamic bone disease. Controversy remains, however,
regarding whether aluminum is responsible for the ady-
namic lesion. In this review, I prefer to use the term
aluminum-induced adynamic bone disease, because the
clinical [3, 5, 10, 15] and experimental evidence [42–44]
suggests that in many cases aluminum is responsible for the
lesion rather than an innocent bystander.
Reports indicate that the incidence of aluminum-induced
toxicity has decreased over the last decade [3, 5, 8], but this
is not true for many developing countries [18, 19], in which
aluminum still is implicated in a high percentage of low-
bone-remodeling lesions. Furthermore, recent series from
Europe and North America reveal that bone biopsies with
substantial amounts of stainable aluminum still are fre-
quent [5, 45, 46]. Even though the finding of aluminum in
the mineralization front does not necessarily mean that
aluminum is the cause of the disease, there is no doubt that
the presence of aluminum, either in the mineralization
front or inside the trabeculae, represents a potential haz-
ard, particularly in patients who undergo parathyroidec-
tomy [47–49], like the patient presented in this Forum.
The presence of aluminum in bone may or may not be
associated with aluminum-induced toxicity. If histochemi-
cal staining techniques reveal that the trabecular bone
surface is covered at least 25% to 30% with aluminum [3,
10], most investigators would attribute low bone remodel-
ing to the aluminum. I am unsure about aluminum’s
responsibility, however, because I view this threshold of
bone surface covered by aluminum as rather empiric.
Further, I believe that the staining technique, such as the
aurin tricarboxilic acid (aluminon), is not sensitive enough.
Ascribing low-turnover-bone disease either to aluminum
or to non-aluminum factors comes from early studies [50,
51], performed when the amount of aluminum exposure
was very high. Aluminum-induced osteomalacia was the
most common, and almost the only, form of low-bone-
turnover disease. Then, the mean percentage of aluminum
covering the mineralization front, measured by histochem-
ical techniques, correlated better with the histomorphomet-
ric parameters than did the amount of aluminum in bone,
measured by atomic absorption spectrometry [50, 51].
Currently, the amount of aluminum available for deposi-
tion in the mineralization front is lower, and the value of
histochemical staining in the diagnosis of aluminum toxicity
should be reconsidered. The stain currently used most to
detect aluminum is aluminon, which has a low sensitivity.
By contrast, other stains, such as solochrome of azurine,
have performed significantly better, and the latter can
obtain more reliable results in the presence of low alumi-
num concentrations [51, 52].
Because of the reduction in aluminum exposure, we need
more sensitive methods to detect lower concentrations of
aluminum in the mineralization front and also in the depth
of the trabeculae [52]. Unfortunately, most of the recent
series showing a high prevalence of non-aluminum-induced
adynamic bone disease still use only the less-sensitive
aluminon technique to rule out aluminum as the cause [3,
4, 8]. Thus, the prevalence of adynamic bone disease
induced by aluminum might be underestimated.
Aluminum may negatively influence bone metabolism
directly by acting on bone or indirectly by depressing
parathyroid function. One of the first reasons for aluminum
being considered toxic to bone is that aluminum can be
deposited in the mineralization front. The presence of
aluminum in this specific location, between the osteoid and
the mineralized bone, was thought to be a physicochemical
obstacle for calcium deposition [45, 53, 54].
The assumption that osteomalacia resulted mainly from
a defect in bone mineralization was confirmed in experi-
mental studies, which also determined that aluminum’s
toxicity in bone is multifactorial, impairing not only the
mineralization process, but also proliferation and activity of
parathyroid and bone cells. Dissociating aluminum’s effect
on bone from its effect exerted in vivo on the parathyroid
gland (and other endocrine and paracrine influences) is
difficult. But in-vivo experiments confirmed an indepen-
dent and direct effect of aluminum on bone cells. High
doses of aluminum given to azotemic rats decreased both
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osteoblast activity (osteoblast surface) and bone formation
rate (mineralized bone) [44, 45]. However, the decrease in
bone formation rate is much more pronounced than is the
effect on osteoblasts. Thus, the overall effect of heavy
aluminum loads is a greater reduction in mineralized bone
compared with its negative effect on osteoid formation
(osteoblast activity), and the resulting increments in non-
mineralized osteoid (increased osteoid volume). In sum-
mary, high doses of aluminum induce the typical lesions of
osteomalacia, and a high percentage of the osteoid surface
is covered by aluminum [10, 15, 44, 46].
Infusion of PTH partly reverses the toxic effect of
aluminum on bone cells, increasing their number and
activity, but PTH supplementation does not improve the
defect in mineralization caused by aluminum [55]. Evi-
dence from in-vitro studies demonstrates that calcium
influx and efflux from bone cells is altered [43] and also that
calcium uptake from bone cells might be decreased [42, 56].
Both these changes impair calcium apposition, crystalliza-
tion, and consequently bone mineralization.
What happens in bone when moderate but long-term
aluminum exposure occurs? The answer is unclear and
awaits studies using experimental models in which alumi-
num is administered in a fashion comparable to the current
aluminum exposure in dialysis patients.
Apart from the just-described direct effects of aluminum
on bone turnover, aluminum also might have an additive
effect on bone metabolism: it interferes with PTH function
and in turn influences bone remodeling. Aluminum can
reduce serum levels of PTH via two main pathways: acting
directly on parathyroid synthesis, degradation, or release,
and indirectly by elevating serum calcium, which in turn
suppresses parathyroid activity [53, 57–60].
Several clinical and experimental studies have shown that
aluminum can directly reduce PTH [37, 38, 55, 58, 59–61].
A series of experiments, carried out by our group some
years ago, gave support to the hypothesis that aluminum
interferes mainly with PTH release and/or degradation [61,
62] rather than with PTH synthesis. Nevertheless, high
doses of aluminum were needed to suppress PTH release
[61]. We proposed that aluminum (AL31) produces a
prompt and direct response—within a few minutes—likely
acting at ionic levels [59, 61], as calcium does, possibly
influencing the calcium-sensing mechanism. The recent
demonstration that the calcium-sensing receptor is sensi-
tive to other bi- and trivalent ions [63] makes our hypoth-
esis quite possible [59].
More recently, preliminary studies have suggested a
reduction in RNA messenger of PTH in rats with acute
aluminum loads; these early data suggest that aluminum
reduces PTH synthesis [64]. Recent preliminary experimen-
tal results suggest that aluminum is taken up by the gland
via the transferrin receptor [65].
In addition to aluminum’s direct effect on the parathy-
roid gland, it might exert a suppressor effect on PTH
indirectly by elevating the serum calcium level [53, 60].
Patients with low bone remodeling, either with osteomala-
cia or adynamic bone disease, have a decreased ability to
buffer calcium loads [40]. Since the first descriptions of
aluminum-induced bone toxicity, we now know that these
patients are more likely to have serum calcium elevations
and to develop hypercalcemia [5], either spontaneously or
when receiving calcium salts or vitamin D therapy.
The mechanisms by which aluminum indirectly decreases
PTH release by elevating serum calcium are easily ex-
plained when one considers where and how aluminum
accumulates. When the aluminum load is high, a large
amount of aluminum is deposited in the mineralization
front. This deposition interferes with the incorporation of
calcium into osteoid. The prevention of calcium deposition
in bone changes the normal calcium equilibrium between
extra- and intracellular compartments; this situation, char-
acterized by an increase of calcium in the extracellular
pool, results in elevated serum calcium levels, in turn
suppressing the synthesis and release of PTH [54, 60].
Aluminum’s suppressive effect on parathyroid function,
no matter what the mechanism, is extremely important for
several reasons. As has been known for decades, chronic
renal failure is characterized by a skeletal resistance to
PTH; thus one needs higher levels of PTH to maintain
adequate bone remodeling. In addition, however, a higher
PTH level is desirable whenever aluminum overload exists.
Evidence suggests that aluminum’s toxic effect on bone is
modulated via serum PTH levels. When enough PTH is
present, that is, when high bone remodeling is the back-
ground, the toxic effect of this metal in bone decreases
despite high bone concentrations of aluminum, and the
likelihood of low bone remodeling is lower.
This phenomenon occurs even though high PTH levels
can increase aluminum uptake in different tissues [59]
without affecting bone remodeling. Thus, a paradoxical
situation might exist in which high PTH levels favor alumi-
num accumulation in tissues but the toxic effect of alumi-
num on bone is lessened, probably because of high bone
turnover induced by PTH. Adequate PTH levels thus seem
to provide significant protection against aluminum toxicity
in bone. The protective role of PTH is apparent from
clinical and experimental studies [47, 48, 56], which dem-
onstrate the high risk of aluminum-induced low-bone-
turnover disease after parathyroidectomy. The case pre-
sented in this Forum is a good example of that risk.
In summary, I would suggest that aluminum’s effect on
mineral metabolism, and ultimately on bone, differs ac-
cording to the timing and amount of aluminum exposure.
With heavy aluminum loads, the predominant effect is a
defect in mineralization that produces osteomalacia. How-
ever, low-moderate aluminum exposure, as in the range of
dialysis patients today, together with reduced levels of PTH
because of the widespread use of vitamin D metabolites
and/or calcium salts, produce a different effect on mineral
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metabolism. These less-severe exposures induce a pattern
of bone damage similar to that in adynamic bone disease.
Because aluminum has an independent effect on the para-
thyroid gland, I don’t think we can eliminate a role for
aluminum in the pathogenesis of adynamic bone disease.
One can reasonably speculate that changes in the pattern
of aluminum toxicity in bone are partly due to the changes
in the pattern of aluminum exposure. In the late 1970s and
early 1980s, dialysis patients were heavily aluminum over-
loaded. Fortunately, apart from sporadic episodes of alu-
minum exposure [66, 67], in most centers massive alumi-
num loads have given way to moderate loads. We and
others have stressed that the widespread use of adequate
water treatment systems and the reduction in the consump-
tion of aluminum hydroxide have dramatically reduced
aluminum overload in patients with chronic renal failure
[16, 67]. However, aluminum exposure has not disap-
peared, and many patients are still permanently exposed to
moderate loads of aluminum both via dialysis fluids and
through oral aluminum hydroxide intake [16].
In the field of prevention of aluminum toxicity, we are
still using the conceptual framework we adopted nearly 15
years ago, when heavy aluminum exposure occurred. Var-
ious governments still accept 10 mg/liter as a safe limit for
aluminum concentration in dialysis fluid. This figure de-
rives from the early 1980s, when many dialysis patients had
serum aluminum values in the range of 100 mg/liter to 200
mg/liter. Considering that only 10% to 15% of aluminum is
dialysable (the remaining 85%–90% is protein bound), the
figure of 10 mg/liter seems a reasonably safe upper limit.
However, in almost all countries, mean basal serum alumi-
num levels of patients on dialysis have fallen significantly.
In Spain, this figure is close to 20 mg/liter; thus, the
aluminum concentration in the dialysate should not exceed
2–3 mg/liter. Yet even in recent reports, the figure of 10
mg/liter of aluminum in dialysis fluids is still perceived as
safe.
The other important source of aluminum exposure,
aluminum hydroxide intake, also has been reduced. Even
though other aluminum-free phosphate binders such as
calcium acetate, calcium carbonate, and others are widely
used, a high percentage of patients, at least in Europe (42%
to 75%), still receive aluminum hydroxide alone or in
combination with calcium salts [24].
Bone biopsy specimens from patients who started dialysis
during the last decade in Europe, in centers that have used
adequate water treatment systems and low doses of alumi-
num-containing phosphate binders for more than 15 years,
still reveal aluminum concentrations in bone 20 to 50 times
higher than normal values [5, 58]. Despite these high
concentrations of aluminum in bone, however, the distri-
bution of aluminum into the bone has changed, and its
concentration in the mineralization front is lower.
As I mentioned earlier, aluminon, the most widely used
staining method for aluminum detection, has a low sensi-
tivity and thus leads to negative or weakly positive results in
contrast to positive results using solochrome of azurine
[52]. This technical error contributes to the widespread,
erroneous concept that aluminum exposure and toxicity no
longer occur. We still do not know the significance and the
toxic role of this different distribution of aluminum in bone,
but if we are to indict or eliminate aluminum as toxic to
bone in an individual patient, we cannot use the same rules
that we used to diagnose osteomalacia in the past.
Aluminum and iron have some similar biochemical prop-
erties, and they share important biologic pathways [68]. For
example, they compete for the same mechanisms of gastro-
intestinal absorption and cellular uptake [69], are carried
by the same serum proteins, are chelated by the same drugs
[68], are stained in bone with the same compounds (alumi-
non and solochrome of azurine), and both have been
implicated in the pathogenesis of low bone remodeling [53,
70, 71]. Therefore, iron toxicity must be considered when
evaluating patients with low bone turnover.
It is beyond the scope of this Forum to discuss in detail
the aluminum-iron interaction [69–71], but I shall briefly
summarize the most relevant aspects of this relationship
and its likely links with low bone turnover. Iron overload
has negative effects on bone [71, 72]. In acute experimental
studies, iron overload did not affect bone mineralization,
but did decrease osteoblast number and activity [72].
Experimental studies did not demonstrate any effect of iron
overload on PTH, but the assay used in these experimental
studies lacks sensitivity [72]. Clinical studies in patients with
hemochromatosis [73] and in patients with renal failure and
iron overload demonstrated a decrease in bone mineral
density and the presence of adynamic bone, respectively.
On the other hand, although a recent study failed to
show any influence of iron stores on aluminum metabolism
[74], several studies from different groups have found an
inverse and competitive relationship between iron and
aluminum metabolism [69, 75–77]. Iron overload decreases
aluminum absorption (thus decreasing the changes of
aluminum overload), aluminum binding to transferrin, and
aluminum cellular uptake. On the other hand, iron deple-
tion (frequently present when patients are treated with
both erythropoietin and deferoxamine) facilitates the de-
velopment of mild to moderate aluminum toxicity and with
it the risk of low bone turnover. Therefore, the two
extremes of this spectrum—high aluminum-low iron, and
high iron-low aluminum—can be implicated in the patho-
genesis of low-bone-remodeling lesions. In addition, recent
preliminary findings suggest that strontium induces low
bone remodeling [78].
Non-aluminum-induced adynamic bone disease. I have
extensively discussed the association of relative PTH defi-
ciency with low bone remodeling. I previously used the
term “aluminum-induced bone disease” to refer to the
low-bone-remodeling disorder induced by aluminum. By
contrast, in the analysis of other causes of adynamia, I will
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use the term “adynamic bone.” As I have already stressed,
the factors to be discussed can cause adynamic bone, but
not necessarily a disease.
Calcium loading decreases PTH synthesis and release by
a direct effect, but calcium loading also might have a direct
negative effect on bone. Some authors have speculated that
excess calcium saturates the sites of bone calcium exchange,
increasing the risk of adynamic bone [40].
In addition, while first reports on the existence of
adynamic bone unrelated to aluminum failed to show any
influence of calcium, more recent reports have found
higher levels of serum calcium and a much higher intake of
calcium carbonate in patients with adynamic bone [3, 5, 8,
9, 79]. Hypophosphatemia also can reduce PTH secretion,
and thus it can be involved in the pathogenesis of low bone
turnover. In several reports, particularly involving CAPD
patients, lower serum phosphate levels have been linked
with adynamic bone [5, 9, 79]. Calcitriol can suppress PTH
indirectly (by raising serum calcium) and directly through
its action on vitamin D receptors in the parathyroid gland
[16, 80, 88]. In addition, as previously discussed, intermit-
tent pulses of calcitriol have a direct suppressive effect on
bone [29, 30]. This direct inhibitory effect of calcitriol on
bone cannot be detected with sequential PTH measure-
ments, because this effect is independent of PTH levels,
which can remain high [29]. New vitamin D metabolites,
with a likely lower direct inhibitory effect on bone, are
undergoing experimental and clinical investigation [82].
The way in which calcitriol directly depresses bone
activity is not fully understood. Calcitriol, an important
regulator of osteoblastic activity, promotes the differentia-
tion of osteoblastic precursors into mature osteoblasts,
enhancing alkaline phosphatase and osteocalcin activity
[29, 83]. By contrast, calcitriol also can reduce collagen
synthesis by osteoblasts [83]. Lastly, during high and inter-
mittent doses of calcitriol, changes in the expression of
vitamin D receptor (VDR) in bone occur [29]. I believe that
the scant human data available suggest that intermittent
calcitriol therapy reduces the activity of differentiated
osteoblasts and chondrocytes [84].
The complex interrelationship among calcium, phospho-
rus, and calcitriol, and the effect of this triad on bone
metabolism, seems best expressed in CAPD patients. In the
most recent series, the prevalence of patients with ady-
namic bone is higher in CAPD compared with hemodialy-
sis, ranging from 22% to 61% [3, 4, 9, 84]. The frequency of
adynamic bone disease in CAPD also was reported higher
in two large series that analyzed 2248 bone biopsy speci-
mens from North America [5, 6] and 1429 bone biopsies
from Italy [46]. This higher incidence of adynamic bone in
CAPD patients likely results from continuous exposure to
high calcium levels in the dialysate, stabilizing serum
calcium at higher levels and, in turn, leading to more
marked PTH suppression. The dialysance of PTH in CAPD
patients also leads to a greater reduction in PTH levels in
this population of patients. Similarly, the higher clearance
of phosphorus observed in CAPD, leading to lower serum
phosphate levels, also would lead to a higher incidence of
adynamic bone disease in this setting [79]. Since CAPD
patients frequently are older [3, 8] and more likely to be
diabetic, these two factors also might play a role. Let me
turn to this issue and to the important effect of acidosis on
bone metabolism.
The growing incidence of patients with adynamic bone
temporally coincides with the increasing use of bicarbonate
(instead of acetate) as a buffer in hemodialysis patients.
The resulting more stable control of acid-base balance is
likely to be one of the factors responsible for the higher
incidence of adynamic bone. Acidosis inhibits osteoblastic,
and stimulates osteoclastic, activity in vitro [27], and stim-
ulates bone resorption in animals [85] and in patients on
dialysis [26]. Therefore, the widespread use of bicarbonate
as the dialysate buffer (along with more widespread use of
oral calcium carbonate) likely has contributed to decreas-
ing the incidence of the high-bone-remodeling disorder
[86].
Studies in the 1980s and 1990s showed that diabetic
patients have a lower incidence of hyperparathyroidism
than do non-diabetic patients; they also have only a mod-
erate increase in bone activity [22, 23]. These observations,
coupled with the growing number of diabetic patients in
CAPD and hemodialysis programs, may partly explain the
increase in low bone remodeling now seen [20, 21]. The
major explanation for the low bone remodeling in diabetics
seems to be the lower PTH levels. The factors possibly
responsible for relative hypoparathyroid function in diabe-
tes are: vascular disease of the parathyroid gland [22] and
the effects on bone of the metabolic derangement of
diabetes per se [87, 88]. Vascular disease of the parathyroid
gland is a reasonable and convincing explanation. Diabetic
patients often have widespread and severe vascular disease;
thus one might speculate that the parathyroid gland also
might sustain vascular damage.
Insulin and hyperglycemia inhibit PTH secretion [88],
but also can have a direct effect on bone. Recent experi-
mental studies in rats suggest that poor control of diabetes
results in a decreased osteoblast surface and bone forma-
tion rate, independent of PTH levels [87]. Moreover, serum
from patients with poorly controlled diabetes inhibits hu-
man osteoblast growth in vitro [89].
Age is another independent factor involved in the patho-
genesis of low bone remodeling. Most regular dialysis
programs no longer impose age restrictions. As a result, the
dialysis population is aging, especially the CAPD popula-
tion. Thus it is difficult to separate the effects of age from
those of CAPD. Nevertheless, age seems to be an indepen-
dent risk factor for the development of adynamic bone [5,
8]. The observation that age affects bone metabolism is not
new. Bone turnover decreases with age. Thus, not too
surprisingly, the quality and quantity of bone remodeling
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differ markedly at age 30 or 70. It seems reasonable to
expect a higher incidence of adynamic bone as the age of
the dialysis population rises. Whether adynamic bone in the
aged is a disease or simply part of the physiologic response
of the aging skeleton is not clear.
Low levels of estrogens, androgens, and thyroid hor-
mones can cause low bone turnover [28], but these disor-
ders need to be considered only in specific cases. Of greater
importance in causing low bone remodeling are corticoste-
roids and other immunosuppressors. Renal transplant pa-
tients receive corticosteroids and immunosuppressors such
as cyclosporine for years. Both groups of drugs have clear
negative effects on bone metabolism, as recently reviewed
in a Nephrology Forum [18]. I need not review this subject
in detail. However, it is important to emphasize that the
evolution of bone lesions after successful renal transplan-
tion is greatly affected by the type of bone lesions present
at the time of transplantation [18, 90–93]. Additional
factors such as cytokines, the polymorphisms of genes, and
changes in the expression of different receptors involved in
bone metabolism recently have been implicated in the
pathogenesis of the different forms of renal osteodystrophy
and in the response to therapy [2, 92–95].
All these factors might contribute to the increasing
frequency of adynamic bone in chronic renal failure. In
some circumstances—for example, aging—low bone re-
modeling might not represent a disease, but in other
circumstances, low bone remodeling definitely should be
considered a disease.
Diagnosis
Low bone turnover can manifest as fatigue and lack of
bone strength; it also increases the risk of fracture. How-
ever, expression of these signs and symptoms is confined for
the most part to the aluminum-induced form of this
disorder. In contrast, the majority of patients with low bone
remodeling we see now are free of symptoms, and many of
them should not be considered as having disease. Most of
the evidence in patients with low bone remodeling indicates
that the incidence of bone pain, hypercalcemia, and bone
fractures is related to the presence of more than 20% of
bone surface covered by aluminum [3, 37]. It remains a
matter of debate whether moderate aluminum-induced or
non-aluminum-induced adynamic bone will become symp-
tomatic in the long term. In any case, signs and symptoms
appear late in the development of low-bone-turnover dis-
ease, and more sensitive and precise markers need to be
used for early diagnosis.
Among the non-invasive markers, the most widely used is
the basal serum PTH level, which I already discussed. To
summarize, basal serum PTH levels lower than 200 pg/ml
should alert us to the possibility of low bone remodeling.
Values in dialysis patients lower than 125 pg/ml have a
positive predictive value for low bone remodeling of ap-
proximately 90% [4]. In predialysis patients with advanced
renal failure, a PTH value of approximately 300–375 pg/ml
is needed to achieve adequate “normal” bone turnover.
To determine whether aluminum is involved in low bone
remodeling, direct measurement of serum aluminum
should be carried out. Over the last two decades, the levels
of “normal, acceptable, and safe” serum aluminum values
in dialysis patients have been dramatically reduced. At
present, I consider acceptable serum aluminum values
lower than 20 mg/liter (reference values in controls with
normal renal function: 2 mg/liter); values from 20 to 60
mg/liter raise the possibility of aluminum overload. Re-
peated values higher than 60 mg/liter are indicative of
aluminum toxicity.
Even though serum aluminum levels better reflect acute
rather than chronic aluminum exposure, serial measure-
ments of serum aluminum concentration correlate with
aluminum concentration in tissues. If the serum aluminum
values vary or are always in the borderline area (20 to 60
mg/liter), the deferoxamine challenge test can help in the
evaluation of the total-body burden of aluminum. While
controversy remains regarding what level of response is
positive [16, 41, 96], in general terms, any increment in
serum aluminum after infusion of deferoxamine indicates
an excess of aluminum in tissues. Depending on the dose
(5–15 mg/kg) of deferoxamine used [20], a rise in serum
aluminum of 50 mg/liter to 100 mg/liter, or simply a twofold
increase from serum basal aluminum values, strongly sug-
gests an excess of aluminum in tissues.
The deferoxamine test has several limitations in its
interpretation, such as a high number (up to 45%) of
false-negative results [17, 97]. Difficulties in comparing the
results of deferoxamine tests are due to differences in
doses, method of administration, and differences in iron
status of the patients [97]. In general, patients with iron
depletion are more likely to have greater increments in
serum aluminum after deferoxamine infusion, compared
with iron-replete patients [97].
Osteocalcin, total alkaline phosphatase, and bone alka-
line phosphatase also are useful in the non-invasive diag-
nosis of low bone turnover; the last seems to be the most
promising among these biochemical markers [98]. These
markers directly reflect bone activity and are of particular
interest in patients receiving calcitriol by pulse therapy.
Since pulse calcitriol inhibits bone turnover without neces-
sarily reducing PTH measurements [29, 30], markers other
than PTH must be utilized. Serum pyridinoline might have
a place in the assessment of low bone remodeling [99], but
further studies are required. In general, the available serum
markers have their greatest utility in separating high- from
low-bone-turnover forms, as well as identifying the degree
of high bone turnover. However, they do not at present
allow us to recognize different types and degrees of low
bone turnover.
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The different imaging techniques, radiology, 99mtechne-
tium bone scans, and bone mass measurement with quan-
titive computerized tomography (QCT) or dual energy
x-ray absorptiometry (DEXA), unfortunately remain of
limited value in the evaluation of low bone remodeling.
Radiologic changes appear too late in the development of
low bone remodeling. Bone scans are not better than
biochemical markers in separating high and low bone
remodeling; DEXA or even QCT can help in the demon-
stration that low-bone turnover is associated with low bone
mass. The main value of imaging techniques resides in their
utility in long-term followup.
To accurately diagnose low bone remodeling, and to
determine whether aluminum is involved in this disorder, a
bone biopsy is required. It is beyond the scope of this
review to analyze the histologic findings of osteomalacia or
adynamic bone; these entities are discussed extensively
elsewhere [3, 4, 8, 10]. By definition, low bone remodeling
implies a reduction in bone formation rate; thus, given the
limitations of the noninvasive tests discussed, bone biopsy is
the only method that can provide a definitive diagnosis.
Management
In managing patients with low bone turnover, it is
essential that one start from the basic concept that two
main forms of low bone remodeling exist: aluminum-
induced and non-aluminum-induced low bone remodeling.
By definition, both forms (independently of the presence or
absence of symptoms) have low bone formation rates and
excessively low PTH levels. Thus, in both forms of low bone
remodeling, excessive PTH suppression must be avoided.
Maintenance of an appropriate PTH level requires avoid-
ance of high calcium dialysate or inappropriate amounts of
calcium supplements and vitamin D metabolites. Using a
normal-low calcium dialysate concentration of 1.25 mM for
long periods results in significant rises in PTH [100, 101].
This active approach designed to increase PTH levels from
excessively suppressed values and, in turn, bone turnover is
useful in selected patients with low bone remodeling. I do
not believe it is advisable to use this approach as a general
strategy for all dialysis patients because, in many, PTH
values rise to excessively high levels and cause high-bone-
remodeling disease [101].
If aluminum is responsible for low bone remodeling, the
aluminum overload must be reduced. The first goal in such
patients must be to avoid further aluminum exposure,
either via dialysate or orally. Using even the most effective
techniques to remove aluminum, the total amount of
aluminum eliminated via dialysis is very low, on the order
of micrograms per dialysis session. Similar amounts of
aluminum can enter the patient if oral aluminum hydroxide
is used, or if the dialysate contains a few mg/liter of
aluminum more than the “dialyzable aluminum” of the
patient (10%–15% of total serum aluminum). An alumi-
num concentration of 2 mg/liter in the dialysate is the best
guarantee of successful removal of aluminum. Second, to
augment aluminum removal, the use of highly permeable
membranes or techniques that combine more than one
method of blood cleansing (for example, paired filtration
dialysis or charcoal cartridges) is required. However, the
beneficial effect of a highly permeable membrane or a
more effective dialysis technique is overridden if the alu-
minum concentration in the dialysate exceeds 5 mg/liter.
The third step involves the use of deferoxamine to
increase the gradient of ultrafiltrable (dialysable) alumi-
num between patient and dialysate. Deferoxamine draws
aluminum from tissues; thus it raises the serum aluminum
levels, increasing the gradient. Over the last decade, we
have reduced the dose of deferoxamine used to treat
aluminum overload. We also have employed different
schedules of deferoxamine administration to decrease its
major side effects [102, 103]. Even though 5 mg/kg is the
current recommended dose, recent studies suggest that
doses as low as 2.5 mg/kg, or even 0.5 mg/kg, are effective
in removing aluminum [104].
Finally, several studies have shown that successful renal
transplantion is probably the most effective way to treat
aluminum-induced low bone remodeling [18, 105]. This
also might be the case with non-aluminum-induced low
bone remodeling, but little information is available. A
recent report demonstrated the presence of adynamic bone
7 years after renal transplantation in as many as 80% of
patients [106]. By contrast, another preliminary report
found a normal bone formation rate in non-aluminum-
induced low bone remodeling one year after transplanta-
tion in 23 patients [107]. Differences in the bone microen-
vironment, in PTH levels, and in the responsiveness of
bone receptors to PTH might help explain these contradic-
tory preliminary results.
Final remarks
In conclusion, the low-bone-remodeling form of azote-
mic osteodystrophy does not represent a single entity.
Rather, it represents a useful concept for grouping the
various mechanisms that can result in this particular re-
sponse of the skeleton during azotemia. While noninvasive
diagnostic tests can help separate this entity from the
high-bone-remodeling form of azotemic osteodystrophy,
bone biopsy is the only sure way to diagnose this histologic
syndrome.
Some patients with low bone remodeling, especially
those with aluminum-induced disease, need more active
medical management; other patients need only preventive
methods to avoid unnecessary suppression of parathyroid
hormone and bone turnover. The evolution of this bone
lesion depends heavily on aluminum, first by its direct effect
on bone, and second by its suppressive effect on the
parathyroid gland.
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QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean of Medicine, Tufts Uni-
versity School of Medicine, Boston, Massachusetts, USA):
Given the high prevalence of the various forms of meta-
bolic bone disease in chronic renal failure, would it not
make sense to perform a bone biopsy early in the course of
renal osteodystrophy, or at least in patients with suspected
aluminum intoxication? I understand that the procedure is
relatively simple and that the morbidity and mortality are
extraordinarily low. Should we be more active in suggesting
bone biopsies to our patients?
DR. CANNATA: I do not think we should perform a bone
biopsy in all patients with chronic renal failure. This policy
should be followed only by specialized groups under spe-
cific research protocols for the purpose of learning more
about metabolic bone diseases at different stages of chronic
renal failure. For clinical purposes, I do think that neph-
rologists should obtain more bone biopsies than they do.
There is no reason to be afraid of bone biopsy. There is
more risk in treating a patient for a long time with an
unclear diagnosis than in establishing the diagnosis with a
bone biopsy, and then treating the patient using more
objective data. Bone biopsy is particularly helpful in pa-
tients in whom the biologic markers suggest a low-bone-
modeling state and in whom we have reasonable doubts
about the participation of aluminum in the bone lesion.
Bone biopsies also are warranted in some patients with
hyperparathyroidism who have been treated with vitamin D
metabolites and in whom the PTH levels might not reflect
what is happening in the bone. I also advise bone biopsy for
any symptomatic patient. From the clinical point of view,
bone biopsy should be used whenever the diagnosis is not
clear.
DR. HARRINGTON: Have any of your patients died as a
result of a bone biopsy? What is the worst outcome of bone
biopsies in your own institution?
DR. CANNATA: Bone biopsy is a very safe procedure. We
have not had any important complication, either in patients
with osteoporosis or in patients with renal osteodystrophy.
The main complication of the bone biopsy is hematoma,
which occurs in not more than 3% of patients [108]. Some
patients experience discomfort or pain, but these symptoms
can be easily resolved with analgesic medications.
DR. MANUEL MARTINEZ-MALDONADO (Emory University
School of Medicine, Atlanta, Georgia, USA): I want to talk a
little bit about the role of acidosis. Many years ago, it was
demonstrated that bone participates in buffering acidosis
but suffers demineralization in the process [109]. You
mentioned that correction of acidosis with bicarbonate and
calcium carbonate has increased the incidence of bone
disease. Would you please explain how that occurs?
DR. CANNATA: It is well known that acidosis has a
negative effect on bone because it induces bone loss.
Therefore, if you correct acidosis, you might expect a
change in bone metabolism but not an increase in the
overall incidence of bone disease. With the correction of
acidosis, we should expect a decrease in bone turnover and
possibly a change in the pattern of the bone disease. The
increasing use of bicarbonate as a buffer in dialysate,
instead of acetate, has led to a better correction of acidosis,
and this fact might partly explain the increased incidence of
low bone remodeling in dialysis patients. I do not imply that
correction of acidosis is a problem; on the contrary, better
correction of acidosis might contribute to a decrease in
bone resorption. In addition, data in hemodialysis patients
demonstrate a reduction in the serum levels of biochemical
markers of bone resorption when you change acetate for
bicarbonate [86].
DR. MARTINEZ-MALDONADO: Are there any data suggest-
ing that extracellular or intracellular pH is significantly
altered in either low or normal bone remodeling? Has
anybody used biopsies to determine whether control of the
intracellular pH induces either low or high bone remodel-
ing?
DR. CANNATA: To my knowledge there are no data on
bone biopsies and intracellular pH. However, experimental
evidence from cultured neonatal mouse calvariae suggests
that metabolic acidosis inhibits osteoblastic, and stimulates
osteoclastic, activity, whereas metabolic alkalosis increases
osteoblastic collagen synthesis [27].
DR. MARTINEZ-MALDONADO: What is the incidence of
adynamic bone disease in areas where aluminum toxicity
has been controlled? Is the incidence related to alterations
in acid-base status? How might acidosis contribute to this
bone disease?
DR. CANNATA: Before answering your question, I want to
emphasize one important concept that technically is not
related to the effect of acid-base balance on bone but is
related to the concept of how to elucidate the role of
aluminum in bone disease. There is a tendency among
some nephrologists (which I do not share) to exclude the
participation of aluminum in bone disease, simply if the
concentration of aluminum in the dialysate is below 10
m/liter or 15 mg/liter, or if less than 15% or 25% of the bone
surface is covered by aluminum, using aluminon as a
marker. I have emphasized that, at present, I do not believe
this is the right way to exclude the participation of alumi-
num in bone lesions. Over the last 10 years, we have
analyzed many bone biopsies from patients who had been
previously classified as having had bone lesions not due to
aluminum. We have found a high percentage of the surface
covered by aluminum (using solochrome of azurine), and
we also have found very high aluminum concentrations in
bone measured by atomic absorption spectrometry, in some
patients an aluminum level as high as 50–70 mg/g. The
normal value of aluminum in bone can reach 2–3 mg/g.
Now let me address the first part of your question. In
places where aluminum exposure seems to not be a com-
mon clinical problem, the prevalence of adynamic bone
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disease still seems high. It is very likely that other factors
that I mentioned explain the decrease in high bone turn-
over disease and the increase in low-bone-turnover disease.
In regard to your followup question on acidosis, as I
mentioned, better control of acidosis has led to a decrease
in bone resorption. Consequently, this change must be
considered one of the factors responsible for the increment
in the prevalence of low bone turnover in dialysis patients.
DR. PABLO MASSARI (Nephrology Chief, Hospital Privado,
Universidad Cato´lica, Co´rdoba, Argentina): It has been
suggested that adynamic bone disease is a marker of poor
survival on hemodialysis, even if you correct for age and
diabetes. Could you comment on the mechanism and the
possible cause of death in these patients?
DR. CANNATA: The information I am aware of demon-
strates that the morbidity of adynamic bone disease is
directly related to the presence of aluminum. The higher
the aluminum in bone, the greater the presence of symp-
toms. In the preliminary results of the 5-year followup from
the Toronto study, it seems that there is an increase in
morbidity, mainly fractures, and in mortality in patients
with adynamic bone disease in whom aluminum exposure is
mild. As patients with adynamic bone disease are older
than patients with high bone turnover, the increment in
mortality has been partly attributed to this factor. However,
we cannot rule out the possibility that the presence of low
bone remodeling itself is, in some circumstances, a marker
of poor health.
DR. MASSARI: Is there any study looking at the time it
takes for aluminum to completely disappear from the bone
with different deferoxamine doses?
DR. CANNATA: Deferoxamine removes aluminum from
different tissues, including bone, but unfortunately, the
total amount removed by deferoxamine is small (measured
in micrograms). You can reduce the aluminum concentra-
tion in bone (a few mg/g of tissue), but we are far from
totally eliminating aluminum from bone. A great part of the
benefit to bone metabolism that we gain by using long-term
deferoxamine administration is related not only to the
removal of aluminum from the bone mineralization front,
but also is related to the removal of aluminum from the
parathyroid gland. The improvement of bone remodeling
correlates more with the increments in circulating PTH
levels than with the reduction of aluminum in bone. This is
why I stress the prevention of aluminum exposure; alumi-
num removal is not easy, and it sometimes is insufficient.
DR. NESTOR SCHOR (Professor of Medicine, University of
Sa˜o Paulo, Brazil): All of us know that the number of renal
patients with tuberculosis is increasing. If you have a
patient with tuberculosis, a renal stone, and interstitial
nephritis, do you measure calcitriol or 1-alpha-hydroxy-
lase? Do you also measure angiotensin-converting enzyme?
Could this granulomatous disease participate in adynamic
bone disease?
DR. CANNATA: The patient we described suffered from
tuberculosis, but this occurred many years before the
diagnosis of adynamic bone disease. Thus, I do not believe
that tuberculosis was involved in this patient’s bone disease.
Nevertheless, your speculation is correct. Patients with any
active granulomatous disease can have increased produc-
tion of 1-alpha-hydroxylase from the granulomas. Thus the
levels of calcitriol are high, and consequently PTH can be
further suppressed. This scenario would more plausible if
the patient also were receiving calcitriol. In such a circum-
stance, I think measuring calcitriol levels would be enough.
DR. J. CARLOS AYUS (Baylor College of Medicine, Hous-
ton, Texas, USA): In our unit, one of the most common
causes of renal failure these days is diabetes. The mean age
of our population is about 60 years, and many of the
patients who come to our unit are malnourished. We have
followed these patients for 5 years; the vast majority were
females. At the beginning, PTH levels were very low—in
the range of values able to induce low bone remodeling.
When these patients started to eat better, received more
protein and thus more phosphorus, and also when they
received more-efficient dialysis, their PTH levels rose. At
first, we thought the increase was due to the hyperphos-
phatemia, but when we analyzed the serum phosphate
levels, we realized that none of the patients had become
severely hyperphosphatemic. Nevertheless, the PTH levels
of these patients rose. There was no aluminum exposure,
either through dialysate or oral sources. What do you think
is the reason for that?
DR. CANNATA: It is extremely difficult to explain the
situation of this particular group of malnourished patients.
It looks like a positive effect of the efficient dialysis on the
general condition of health. If you isolate the data on the
increment of phosphorus, it could explain, together with
the better nutrition, the increments in PTH. Experimental
studies have demonstrated that a diet rich in phosphorus
can induce increments in PTH without inducing increments
in serum phosphorus [110]. This could be at least a partial
explanation; however, your example is quite specific, and
many other factors could be involved.
DR. FERNANDO VALDERRA´BANO (Professor of Medicine,
Head, Department of Nephrology, Hospital General Univer-
sitario Gregorio Maran˜o´n, Madrid, Spain): Aluminum inter-
feres with gastrointestinal absorption of iron, its binding to
proteins, and its storage. On the other hand, aluminum
intoxication produces microcytic anemia and also causes
resistance to erythropoietin. Do you think that the resis-
tance to erythropoietin treatment and the microcytic ane-
mia in aluminum intoxication are the consequence of
decreased bioavailability of iron to the bone marrow?
DR. CANNATA: You are correct in suspecting a likely role
in iron bioavailability in aluminum intoxication. As you
know, there is a two-way relationship between iron and
aluminum. It is reasonable to speculate that if iron metab-
olism partially modulates aluminum uptake, the reverse
also is possible. Therefore, in cases of aluminum overload,
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the saturation of extra- and intracellular binding sites with
aluminum might decrease the chances to bind iron. In these
circumstances, iron metabolism might be influenced by
aluminum intoxication. This mechanism could be involved
in the resistance to erythropoietin treatment. One of our
recent goals has been to prove this hypothesis. We have
observed reduced iron absorption in animals with alumi-
num intoxication [77]. Also, in cell culture models, the iron
uptake by intestinal and bone cells is reduced if the cells
have been preloaded with aluminum [77]. These findings
support the hypothesis that in aluminum intoxication, at
least part of the resistance to erythropoietin treatment is
indirectly due to reduced bioavailability of iron.
DR. HARRINGTON: First, are bone fractures equally likely
in patients with high- or low-bone-turnover disease? Sec-
ond, in patients with low-bone-remodeling disease, what
histologic or histomorphometric finding best correlates
with fractures?
DR. CANNATA: High- as well as low-bone-remodeling
diseases can be symptomatic. In addition, they can have
similar symptoms, but the prevalence of bone fractures is
higher in patients with low bone turnover induced by
aluminum. The patient discussed in this Forum is a good
example. It is also likely that the forms of low bone
remodeling in which aluminum participation is null, mild,
or moderate also can have a higher incidence of bone
fractures over the long term. However, the preliminary data
in this field indicate that age also plays a role. It is well
known that the fracture rate due to osteoporosis increases
with age, and patients on dialysis are not excluded from this
group.
Regarding your second question, I am not aware of
specific data relating the incidence of fractures and selected
histologic or histomorphometric parameters. However,
most of the series attributing bone morbidity to aluminum
use the percentage of bone surface covered by aluminum as
the best differentiating marker. Other markers could also
be useful, for example, bone formation rate, but the
problem with this measurement is that when bone remod-
eling is low, it is difficult to establish significant differences
among the biopsies, in turn making it difficult to correlate
this measure with clinical outcomes.
DR. JOAO FRAZAO (Visiting Assistant Professor, University
of California, Los Angeles, California, USA): My first ques-
tion relates to the first part of your talk. You mentioned,
and I agree, that there is a different limit in the amount of
osteoid volume for the diagnosis of aplastic bone—5% in
Dr. Llach’s series, 15% in the Sherrard series. Many of the
patients from Dr. Llach’s series considered to have osteo-
malacia would have aplastic bone in the Sherrard series.
What should be the threshold for osteoid volume in
diagnosing adynamic bone disease?
DR. CANNATA: As a nephrologist, it is difficult for me to
define an upper limit for normal osteoid, especially when
the experts in this field did not reach agreement on that
point. My feeling is that 5% of osteoid volume is an
extremely low limit, but at the same time, 15% is a rather
high limit. Maybe a figure of around 10% to 12% would be
better, but again this is a speculation; I do not have data to
support it.
DR. FRAZAO: Hypercalcemic episodes are seen more
often in patients with low-bone-turnover disease, even in
the cases not related to aluminum. Given this high inci-
dence of hypercalcemia, shouldn’t we always consider low
bone turnover a disease?
DR. CANNATA: You have brought up a very important
issue. It is difficult to know whether we should always
consider low bone turnover a disease. The message I tried
to give in my talk is that we have to put our efforts toward
identifying the cases of low bone remodeling that feature
specific disabling characteristics; these cases need to be
considered a disease. The extremes of the spectrum of
low-bone-remodeling conditions are easy to classify: on one
side, we have the classic examples of low bone turnover as
a disease (that is, aluminum toxicity). On the other side, we
have the cases in which the low bone remodeling is almost
a physiologic condition (that is, age). I believe the appear-
ance of fractures, symptoms, or even hypercalcemia in any
patient with the suspicion of low bone turnover gives us
justification for considering the condition a disease. Even
though we tend to consider hypercalcemia a minor prob-
lem, I don’t believe we should, because the presence of
spontaneous hypercalcemia means a lack of ability to
handle calcium. Patients with this problem will have a
higher risk of developing extraosseous and vascular calcifi-
cations.
DR. JACK W. COBURN (Professor of Medicine, UCLA
School of Medicine, VA Medical Center, Los Angeles, Cali-
fornia, USA): Even though we do not prescribe aluminum
gels in our dialysis units, aluminum gels are still used in
many places. As you discussed, the use of aluminum gels is
dangerous because the bone is more susceptible to alumi-
num toxicity if low bone turnover is present. This is an
added reason why this condition, even though sometimes it
is not a disease, could easily become a disease if aluminum
exposure were high. Thus, in the presence of low bone
remodeling, we unequivocally have to reduce the chances
of aluminum exposure.
I have another comment. Let’s look at patients with very
high parathyroid hormone levels who have either high
serum aluminum levels (above 40 or 50 mg/liter) or who
have been taking aluminum gels. If they have a parathy-
roidectomy for histologically proved osteitis fibrosa, they
have a high likelihood of developing aluminum-induced
bone toxicity. This is the kind of patient in whom a bone
biopsy is warranted before parathyroidectomy.
My question addresses the different responses among
patients. Why is there so much heterogeneity among pa-
tients with regard to aluminum inhibiting parathyroid hor-
mone? Even in days gone by in Newcastle, where there was
Nephrology Forum: Hypokinetic azotemic osteodystrophy1012
aluminum in the water and all the patients were exposed,
still only a small fraction developed hyperparathyroidism.
In this experiment of nature, some patients’ parathyroid
glands were insensitive to suppression of PTH. Do you have
any ideas as to the mechanism?
DR. CANNATA: I do not have a definitive answer. It is easy
to assume that when the source of aluminum exposure is
oral, differences in aluminum uptake observed in different
tissues, including the parathyroid gland, can be at least
partly explained through the different degree of gastroin-
testinal aluminum absorption observed in dialysis patients.
However, when the aluminum exposure is through dialysis
fluids, there is no barrier of protection, such as the gastro-
intestinal tract, and the differences must be explained using
other arguments. The different carriers of aluminum in
serum and its ability to be incorporated in the cells by
receptors might partly explain this phenomenon. We are
now learning about the influence of the different receptors
and their polymorphisms in bone metabolism. It is highly
likely that aluminum uses different receptors when it is
incorporated into cells. Differences in density, affinity, or
characteristics of this active transfer might in the future
give a clue to the individual susceptibility found in some
patients.
DR. JOSE´ R. WEISINGER (Professor of Medicine, Head,
Division of Nephrology, Hospital Universitario de Caracas,
Universidad Central de Venezuela, Venezuela): You men-
tioned that age is a factor related to low bone remodeling.
Many female patients with early menopause and also male
patients with low sexual hormones do not get hormone
replacement. Do you think this situation could be a factor
precipitating low bone remodeling? Should we treat our
ESRD patients who have early menopause with hormone
replacement?
DR. CANNATA: I do not know whether the lack of sex
hormones can precipitate low bone remodeling, but I am
sure that the lack of sex hormones plays a role in the
pathogenesis of bone disease in dialysis patients, as it does
in the general population, particularly in women. If you
consider the mechanism of action of estrogens, the de-
crease in serum levels might favor bone turnover and high
bone resorption; on the other hand, the lack of estrogens
might influence the necessary secretion of PTH. It is also
likely that estrogens change the sensitivity of bone to PTH.
There are no solid data in this field, but I believe that in the
following years we will have an answer to this question. In
Spain we are now setting up a multicenter trial in women
on dialysis to find out the effect of hormone replacement
therapy.
DR. HARRINGTON: Has anyone begun using alendronate
in elderly dialysis patients with known metabolic bone
disease?
DR. CANNATA: Preliminary data presented by Dr. Weis-
inger and Dr. Heilberg at the recent renal osteodystrophy
meeting in Oviedo showed some benefit in using biphos-
phonates in dialysis patients. I do not think this approach
will have benefit in patients with low bone remodeling, but
it will benefit some forms of bone disease, particularly if
bone resorption is high. Biphosphonates also could be used
in cases of high bone remodeling in patients who refuse
parathyroidectomy or in whom a previous aluminum load
makes it inadvisable to remove parathyroid tissue.
DR. I. P. HEILBERG (University of Sa˜o Paulo, Brazil): You
mentioned the direct effect of vitamin D on bone formation
rate. Would you speculate on this mechanism? Do you
think this effect is related to the administered dose or to the
blood level of vitamin D?
DR. CANNATA: Calcitriol suppresses PTH, but it also has
a direct effect on bone cells. This direct effect has been
observed using intraperitoneal and intravenous calcitriol,
but the effect has not been observed using low doses of oral
calcitriol [29]. Considering that you achieve a higher peak
of calcitriol with the parenteral injections, we can speculate
that, at least, this is partly a dose-related effect. Growth
plate and mature bone have a great density of vitamin D
receptors. It appears that if you fully block the receptors,
you obtain undesirable effects in both cartilage and bone.
This is one of the reasons why efforts are in progress to
synthesize new vitamin D metabolites able to act on PTH
but without a marked effect on bone.
DR. ANIBAL FERREIRA (Curry Cabral Hospital, Lisbon,
Portugal): What is your opinion about the role of b-2-
microglobulin and the type of dialysis membrane? Do you
think this factor could play a role in bone cell activation and
bone remodeling and that it might account for the increase
of adynamic bone disease in recent years?
DR. CANNATA: The use of more biocompatible mem-
branes decreases the production of local factors that stim-
ulate bone resorption, such as various cytokines (interleu-
kins, TNFa, etc.). In effect, by using this approach, we are
decreasing the production of substances that negatively
affect bone metabolism, and maybe we are approaching a
more adequate bone remodeling.
DR. HARRINGTON: Given that we can administer hor-
mones like insulin, calcitriol, and erythropoietin, do you
think that in the future we will use parathyroid hormone for
patients who have low PTH levels and also for those who
have had parathyroidectomy?
DR. CANNATA: Thank you for your interesting comment.
This is an open field for research. Several pharmaceutical
companies are investigating new active fragments of PTH
to be used mainly in some forms of osteoporosis, with the
aim of stimulating bone remodeling. These drugs would be
applicable to forms of low bone remodeling observed in
chronic renal failure. If we had the opportunity to admin-
ister PTH, we could increase bone activity with more
precision and also at the level we desire. In addition, we
could use pulses of PTH to obtain a more controlled
activation of bone turnover. This form of therapy would
allow us to avoid the indirect approach of treatment we are
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using now, for example, lowering the calcium level in the
dialysate, with the aim of increasing PTH. Also, PTH
therapy would be useful in patients with PTH suppression
due to aluminum toxicity; increasing PTH levels in turn
would protect bone from the toxic effect of aluminum.
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